CORXEL

Based in Shanghai, China and founded in 2019, CORXEL Pharmaceuticals (Shanghai) Co Ltd. , trading as CORXEL, operates as a drug developer, specializing in providing drugs for the treatment of critical diseases. The CEO, Yanping Mou, graduated from Shanghai Medical College of Fudan University and worked at pharmaceutical companies such as GlaxoSmithKline, AstraZeneca, and Merck Sharp & Dohme. In January 2026, CORXEL raised USD 287 million in Series D1 funding from new investors Adage Capital Management, HBM Partners, Hengdian Capital Management, Invus Financial Advisors, RA Capital Management, SilverArc Capital, SR One, SymBiosis Capital Management, TCG Crossover Management, returning investor RTW Investments, with participation from other investors.

The company’s pipeline consists of small‑molecule therapeutics targeting cardiometabolic indications. Its lead product candidate, CX11, is an oral GLP‑1 receptor agonist currently in Phase 2 clinical trials in the United States and Phase 3 trials in China. Additional programs include JX10 for acute ischemic stroke and JX09, a selective aldosterone synthase inhibitor for hypertension. The company's revenue is generated primarily through equity financing and strategic investment used to support research, clinical development, and global trial execution.

The Series D1 funding raised will primarily be used to advance the development of its investigational pipeline candidate, CX11. In addition, this funding round will also be used to advance other cardiovascular and metabolic projects, including the development of pipelines for acute ischemic stroke and hypertension.